Aug 22 (Reuters) - Alzheimer's patients in Britain's
state-run health service is unlikely to get access to Eisai ( ESALF )
and Biogen's new Leqembi drug, after it was
approved by the country's regulator but deemed too expensive for
wide use on Thursday.